Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies
Authors:
- A H GradmanAGA H Gradman
- M R WeirMWM R Weir
- M WrightMWM Wright
- C A BushCBC A Bush
- D L KeefeDKD L Keefe
- 4 March 2010
- journal article
- research article
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 24 (11) , 721-729
Abstract
Hypertension is a major risk factor for cardiovascular disease, which is the leading cause of mortality in women in developed countries. This pooled analysis assessed the antihypertensive efficacy, safety and tolerability of monotherapy with the direct renin inhibitor aliskiren (150 mg and 300 mg) over 8-12 weeks in women with mild-to-moderate hypertension (mean sitting diastolic blood pressure (msDBP) ≥95 and <110 mm Hg) across eight randomized and double-blind trials. Safety and tolerability were assessed in the five placebo-controlled trials in the analysis. In the 1527 women enrolled in these studies, aliskiren 150 mg and 300 mg produced significantly greater blood pressure (BP) reductions (14.1/11.0 and 16.1/12.3 mm Hg, respectively) compared with placebo (7.2/7.6 mm Hg; P<0.0001). BP reductions with aliskiren monotherapy in women were similar to those observed in men, and consistent across subgroups of age, metabolic syndrome and obesity. The overall incidence of adverse events in women was similar with aliskiren treatment (150 mg, 42.3%; 300 mg, 46.0%) and placebo (39.0%); adverse events with aliskiren were more frequent in women than in men, consistent with previous studies of gender differences in drug tolerability. In conclusion, aliskiren monotherapy at 150 mg and 300 mg doses provided effective, dose-dependent BP-lowering in women with mild-to-moderate hypertension, and it was well tolerated.Keywords
This publication has 48 references indexed in Scilit:
- Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor AliskirenCirculation, 2009
- Heart Disease and Stroke Statistics—2009 UpdateCirculation, 2009
- Menopause and HypertensionHypertension, 2008
- Gender Difference in Blood Pressure Control and Cardiovascular Risk Factors in Americans With Diagnosed HypertensionHypertension, 2008
- AliskirenDrugs, 2007
- Hypertension in Adults Across the Age SpectrumJAMA, 2005
- Hypertension Treatment and Control in Five European Countries, Canada, and the United StatesHypertension, 2004
- Hypertension and Its Treatment in Postmenopausal WomenHypertension, 2000
- Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension StudyArchives of internal medicine (1960), 1996
- Gender as a Risk Factor for Adverse Events to MedicationsDrugs, 1995